We are live on ! Find out more

Treace Medical Concepts

TMCI

Market cap $293M

4.63 USD

+0.12

2.66%

At close Updated Sep 14, 4:00 PM EDT

Pre-market

After hours

4.56

-0.07

1.51%

1 day

2.66%

5 days

-2.53%

1 month

-3.34%

3 months

18.11%

6 months

226.06%

Year to date

85.2%

1 year

-35.87%

5 years

-84.56%

10 years

-81.86%

About: Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The company operates and manages its business as a single segment: designing, manufacturing, and marketing medical devices for surgeons, ambulatory surgery centers, and hospitals related to the surgical management of bunion and related midfoot deformities.

Employees: 450

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 87.5%

Negative 12.5%

Treace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call Transcript

Treace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call Transcript

Treace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call Transcript

Treace Medical Concepts Q2 Earnings Call Highlights

Treace Medical Concepts NASDAQ: TMCI reported second-quarter 2026 revenue of $45.4 million, down 4% from the prior-year period, as lower procedure-kit sales to stocking distributors and a continued shift toward lower-priced minimally invasive products weighed on reported sales.

Treace Medical Concepts Q2 Earnings Call Highlights

Zacks Investment Research

Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates

Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.28 per share a year ago.

Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates

Treace Medical Concepts Reports Second Quarter 2026 Financial Results

PONTE VEDRA, Fla., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related deformities, today reported financial results for the second quarter ended June 30, 2026.

Treace Medical Concepts Reports Second Quarter 2026 Financial Results

Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Treace to Report Second Quarter 2026 Financial Results on August 7, 2026

PONTE VEDRA, Fla., July 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the second quarter 2026 before the start of trading on Friday, August 7, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET.

Treace to Report Second Quarter 2026 Financial Results on August 7, 2026

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Treace Medical Concepts, Inc. (TMCI)

SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Treace Medical Concepts, Inc. (NASDAQ: TMCI) against certain of its officers and directors for alleged breaches of fiduciary duty.

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Treace Medical Concepts, Inc. (TMCI)

Treace Announces First Surgical Case with the HyperPlate™ XM Dynamic Compression Locking Implant System

New portfolio addition to drive further penetration into incremental procedures throughout the foot and ankle; strengthens Treace's comprehensive suite of technologies for its growing customer base New portfolio addition to drive further penetration into incremental procedures throughout the foot and ankle; strengthens Treace's comprehensive suite of technologies for its growing customer base

Treace Announces First Surgical Case with the HyperPlate™ XM Dynamic Compression Locking Implant System

Treace to Present at the Sidoti Small Cap Conference

PONTE VEDRA, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will present at the Sidoti Small Cap Conference, Thursday, June 18, 2026, beginning at approximately 1:45 pm ET.

Treace to Present at the Sidoti Small Cap Conference

Treace Medical Concepts, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Treace Medical Concepts, Inc. (NASDAQ: TMCI). The investigation focuses on Treace's executive officers and whether investor losses may be recovered under federal securities laws.

Treace Medical Concepts, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

See News Rankings

Price charts implemented using Lightweight Charts™